All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BEN-2293
Therapeutic Area: Dermatology Product Name: BEN-2293
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2021
Details:
BEN-2293 is a selective Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FCX-013,Veledimex
Therapeutic Area: Dermatology Product Name: FCX-013
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
The open label, single cohort Phase 1/2 clinical trial is evaluating the safety of FCX-013 as its primary objective. Secondary objectives include assessments of fibrosis at targeted sclerotic lesions at various time points through 26 weeks post-administration of FCX-013.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): XZ.700
Therapeutic Area: Dermatology Product Name: XZ.700
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AMTX-100
Therapeutic Area: Dermatology Product Name: AMTX-100
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
Amytrx is developing AMTX-100, a new anti-inflammatory therapeutic platform, which has broad potential in multiple inflammatory, autoimmune, and metabolic diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: FB-401
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
Details:
Forte Biosciences announced the issuance of its seventh U.S. patent (10,682,379), broadening protection to include methods for culturing gram negative bacteria from the skin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Tocagen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 15, 2020
Details:
As per the merger agreement, stockholders of Forte have become the majority owners of Tocagen, and the operations of Forte and Tocagen have combined.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HST 001
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
This blinded, randomized, placebo controlled, single site study is designed to assess the safety and tolerability of HST 001, and indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HST 001
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2020
Details:
Under this IND, Histogen intends to initiate a Phase 1b/2a clinical trial of HST 001, a Hair Stimulating Complex (HSC), in the second quarter of 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ARQ-252
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Details:
Arcutis has enrolled the first patient in Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of JAK1, in adult patients with chronic hand eczema.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FB-401
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Alger
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Merger February 19, 2020
Details:
The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
